SeQuent Scientific announced that its wholly owned subsidiary Alivira Animal Health (Alivira) through Alivira Ireland, has today signed an agreement with simultaneous closing to acquire 100% of Bremer Pharma, Zydus Cadila's Animal Health Business in Germany.

Bremer Pharma, founded in 1982 is a niche veterinary health company in Germany with focus on cattle and swine segments. Bremer has a portfolio of over 400+ registered products across Europe, Far East, MENA, Russia & Africa operating in vitamins, antibiotics and hormones. Bremer registered sales of €6.7 million (USD 8.3 million) in year ending March 31, 2018 with marginal losses. Bremer comes with a EUGMP compliant injectable manufacturing facility with approval from German Competent Authority LANUV. The site was recently reinspected and obtained a renewed GMP certificate on 12th March 2018.

This acquisition provides Alivira's with a beta-lactam & non-beta lactam injectables facility for EU markets, which compliments its Orals & Powders beta-lactam and non-beta lactam facility based at Barcelona in Spain. EU is Alivira's largest market accounting to 60% of revenues.

With this acquisition, Alivira is a ~USD 150 million business on annualized basis with presence in 95+ countries. Alivira has strong presence in the formulations business in key veterinary markets of Europe, LATAM, India, Turkey, Africa and South East Asian countries. Over 80% of the revenues of Alivira are generated outside India, with manufacturing operations in Spain, Germany, Brazil, India and Turkey and R&D development in India, Turkey and Spain.

In last 36 months Alivira has successfully acquired and integrated over 8 businesses globally. These successful integrations, coupled with commercialization of API’s in US and aggressive new product development program will create sustainable value and speed up the revenue and margin growths in the coming years.

Manish Gupta, Managing Director said, ''We are excited with the addition of Bremer Pharma to the Alivira fold as it consolidates our position as a leading Animal Health Company in the European market. This also provides comprehensive manufacturing footprint in EU across Injectables, Orals, Solids, and Powder range and front-end presence in Top 6 of 10 EU markets. The scale up and growth momentum will further drive the next phase of value creation through accelerated revenues and margin expansion in the business.''

Shares of the company gained Rs 2.25, or 3.3%, to trade at Rs 70.50. The total volume of shares traded was 5,055 at the BSE (10.10 a.m., Wednesday).